

## Publicly Funded Vaccine for High Risk Individuals Autoshipment Agreement

**Communicable Disease Control** 

**Instructions:** Please read and complete this form and fax:

Attention: Toronto Public Health - Blood Borne Diseases and Infection Prevention and Control

Fax #: (416) 338-8440

Refer to the Publicly Funded Immunization Schedule for detailed high risk eligibility criteria and dosing schedule by age.

,	ctice setting (pi	ck one):							
☐ Medic	al clinic								
☐ Hospi	tal or hospital ph	armacy							
□ Other	– describe:_								
2) Physician /	clinic / institutio	on:							
Full Name & Address:			Ordered by (name)			Telephone #			
			OHIP BILLING/GRO	JP # (requ	ired)	Fax#			
See next pag	railable for indiv e for eligible risk	<u> </u>	h risk eligibility crit		Coto	logue No	Doggo	Doguirod	
Vaccine Type		Description		Doses		logue No.	Doses	Required	
HA (adult)	prefilled syringe,	ine, Inactivated Adult, 1	1.0 mL vial or	1	6571-3257-0				
HA		ine, Inactivated Pediatr	ric. 0.5 mL	1	6571-3256-0				
(pediatric)	vial/prefilled syrir	·							
HB (adult)	Hepatitis B Vacci	ne, Adult, 1.0 mL vial,	1/box	1	6571-3243-0				
HB (pediatric)	Hepatitis B Vacc	vial, 1/box	1	65	71-3251-0				
HB (renal)	Hepatitis B Vaccine, 1.0 mL vial, Recombivax® 40 μg per mL, 1/box				6571-3324-1				
HPV-4	18) 0.5mL vial o	avirus Quadrivalent (ty r prefilled syringe		1	65	71-3351-0			
HPV-9	Human Papillom	avirus 9-valent (types se vial or single-dose s		1					
4CMen-B		Multicomponent Meningococcal B Vaccine (Recombinant, 1 6571-3314-0 Adsorbed) 0.5 mL prefilled syringe							
Men-C-ACYW		Conjugate Quadrivalen and W-135) 0.5mL via		1	65	71-3360-0			
Men-P-ACYW	Meningococcal-Polysaccharide Quadrivalent (Groups A, C, Y and W-135) 0.5mL vial				65	6571-3327-2			
Vaccine suppl		shed quarterly. If v		s change	cont	act TPH at	416-33	8-8400	
For TPH office us	se only:								
TPH Clerk: Date Or		Date Order Received:	Confirmation Nu	Confirmation Number:			d		
							☐ Not Approved		



## RISK GROUPS ELIGIBLE FOR PUBLICLY FUNDED VACCINES

See Publicly Funded Immunization Schedule for detailed high risk eligibility criteria and dosing schedule by age.

VACCINE	DESCRIPTION				
HPV-4	Individuals, up to 26 years, who self-identify as MSM (gay, bisexual or transgender); if already started the HPV-4 series				
HPV-9	Individuals, up to 26 years, who self-identify as MSM (gay, bisexual or transgender); if just starting the series				
	Men who have sex with men				
Hepatitis A	(MSM) Injection drug user				
	Chronic liver disease (including chronic hepatitis C				
	infection) Community contact being immunized for				
	outbreak control				
	Men who have sex with men				
	(MSM) Injection drug user				
	Chronic liver disease (including chronic hepatitis C				
	infection) Community contact being immunized for				
Hepatitis B	outbreak control				
	Contact of hepatitis B carrier or case (neonate, household, or				
	sexual) Sexually transmitted infection (STI) case or multiple sexual				
	partners Body fluid exposure (needle stick, human bite)				
	Blood product recipient; dialysis patient				
	HIV positive				
	Asplenia (functional or anatomic)				
	Complement, properdin, or factor D deficiency; primary antibody				
Meningitis	deficiencies Cochlear implant recipients (pre/post implant)				
	Acquired complement deficiency				
	Close contacts of a case of invasive meningococcal disease and during outbreaks caused by <i>N.meningitis</i> groups A, C, Y, W and B				